EDAP TMS S.A. (FOCL)Healthcare | Medical Distribution | Vaulx-En-Velin, France | NasdaqGM
5.43 USD
-0.01
(-0.092%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 5.43 |
Hot Take ↕ | July 11, 2026, 3:24 a.m. EDT
The investment case for EDAP TMS is currently broken by deteriorating fundamentals and a hostile market verdict. The company is bleeding cash, with operating margins at -41% and free cash flow in the negative millions, while the balance sheet carries debt against minimal equity. This financial distress is reflected in the stock's brutal multi-year performance, which has erased more than half of its value over the last nine years. Although the company recently pivoted to focus exclusively on robotic focal therapy, the market has not yet rewarded this strategic shift; the stock remains deeply depressed relative to its historical highs. The absence of any dividend yield eliminates a floor for investors, forcing reliance on capital appreciation in a business that is currently unprofitable. While the stock trades at a low absolute price, the combination of negative earnings, shrinking margins, and a multi-year downward trajectory suggests the market views the current valuation as appropriate for a distressed asset rather than a bargain. Until profitability returns and the new strategy shows traction, the risk of further downside outweighs the potential for a quick rebound. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.292514 |
| AutoTheta | 0.301685 |
| AutoETS | 0.302073 |
| AutoARIMA | 0.303381 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 4.91 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.089 |
| Excess Kurtosis | -0.13 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 275.141 |
| Revenue per Share | 1.977 |
| Market Cap | 203,527,168 |
| Forward P/E | -9.31 |
| Beta | -0.03 |
| Profit Margins | -41.70% |
| Website | https://investor.focalone.com |
As of July 11, 2026, 3:24 a.m. EDT: Options activity reveals a distinct lack of bullish conviction. Call volume is negligible across all expirations, with open interest concentrated entirely in-the-money strikes, suggesting holders are waiting for recovery rather than betting on further gains. Conversely, put open interest is heavily skewed toward deep out-of-the-money strikes (e.g., $2.50), indicating speculative bets on a significant downside move or a 'catapult' scenario where the stock collapses to test the lows. Implied volatility is extremely low, reflecting a market that has priced out both immediate rallies and standard volatility, leaving only binary outcomes.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.602649 |
| Address1 | Parc dActivites la Poudrette-Lamartine |
| Address2 | 4/6, rue du DauphinE |
| All Time High | 21.64 |
| All Time Low | 0.5 |
| Ask | 5.37 |
| Ask Size | 1 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 34,310 |
| Average Daily Volume3 Month | 39,247 |
| Average Volume | 39,247 |
| Average Volume10Days | 34,310 |
| Beta | -0.034 |
| Bid | 5.43 |
| Bid Size | 1 |
| Book Value | 0.269 |
| City | Vaulx-En-Velin |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | France |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.43 |
| Current Ratio | 1.343 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 5.47 |
| Day Low | 5.39 |
| Debt To Equity | 275.141 |
| Display Name | EDAP TMS |
| Earnings Timestamp End | 1,787,833,800 |
| Earnings Timestamp Start | 1,787,833,800 |
| Ebitda | -22,203,000 |
| Ebitda Margins | -0.29975 |
| Enterprise To Ebitda | -9.742 |
| Enterprise To Revenue | 2.92 |
| Enterprise Value | 216,307,184 |
| Eps Current Year | -0.81 |
| Eps Forward | -0.58333 |
| Eps Trailing Twelve Months | -0.82 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.5286 |
| Fifty Day Average Change | 0.9013996 |
| Fifty Day Average Change Percent | 0.19904597 |
| Fifty Two Week Change Percent | 260.2649 |
| Fifty Two Week High | 5.64 |
| Fifty Two Week High Change | -0.21000004 |
| Fifty Two Week High Change Percent | -0.03723405 |
| Fifty Two Week Low | 1.21 |
| Fifty Two Week Low Change | 4.22 |
| Fifty Two Week Low Change Percent | 3.487603 |
| Fifty Two Week Range | 1.21 - 5.64 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 870,442,200,000 |
| Float Shares | 27,966,059 |
| Forward Eps | -0.58333 |
| Forward P E | -9.308624 |
| Free Cashflow | -10,666,803 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 289 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.43408 |
| Gross Profits | 32,153,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06126 |
| Held Percent Institutions | 0.38874 |
| Implied Shares Outstanding | 37,481,986 |
| Industry | Medical Distribution |
| Industry Disp | Medical Distribution |
| Industry Key | medical-distribution |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. In addition, the company manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters; and sells spare parts and disposables, such as electrodes. Further, it markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales channels, and third-party distributors and agents. The company serves academic, public, and private hospitals, as well as clinics. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop clinical workflows combining PSMA PET imaging and Focal One Robotic HIFU for prostate cancer. EDAP TMS S.A. was incorporated in 1979 and is headquartered in Vaulx-en-Velin, France. |
| Long Name | EDAP TMS S.A. |
| Market | us_market |
| Market Cap | 203,527,168 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_27892 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -30,885,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 204,089,413 |
| Number Of Analyst Opinions | 4 |
| Open | 5.42 |
| Operating Cashflow | -14,039,000 |
| Operating Margins | -0.4136 |
| Payout Ratio | 0.0 |
| Phone | 33 4 72 15 31 50 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 5.43 |
| Post Market Time | 1,783,973,090 |
| Previous Close | 5.435 |
| Price Eps Current Year | -6.7037034 |
| Price Hint | 2 |
| Price To Book | 20.185873 |
| Price To Sales Trailing12 Months | 2.7476938 |
| Profit Margins | -0.41696 |
| Quick Ratio | 0.942 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | -0.00500011 |
| Regular Market Change Percent | -0.0919984 |
| Regular Market Day High | 5.47 |
| Regular Market Day Low | 5.39 |
| Regular Market Day Range | 5.39 - 5.47 |
| Regular Market Open | 5.42 |
| Regular Market Previous Close | 5.435 |
| Regular Market Price | 5.43 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 55,395 |
| Return On Assets | -0.21027 |
| Return On Equity | -1.30468 |
| Revenue Growth | 0.248 |
| Revenue Per Share | 1.977 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 37,481,986 |
| Shares Percent Shares Out | 0.0050999997 |
| Shares Short | 189,418 |
| Shares Short Previous Month Date | 1,778,803,200 |
| Shares Short Prior Month | 57,027 |
| Short Name | EDAP TMS S.A. |
| Short Percent Of Float | 0.0067000003 |
| Short Ratio | 4.29 |
| Source Interval | 15 |
| Symbol | FOCL |
| Target High Price | 10.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 6.875 |
| Target Median Price | 7.25 |
| Total Cash | 15,012,000 |
| Total Cash Per Share | 0.401 |
| Total Debt | 27,792,000 |
| Total Revenue | 74,072,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.82 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.5512 |
| Two Hundred Day Average Change | 1.8787999 |
| Two Hundred Day Average Change Percent | 0.5290606 |
| Type Disp | Equity |
| Volume | 55,395 |
| Website | https://investor.focalone.com |
| Zip | 69,120 |